Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

• Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.

• The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses.

• At week 16, patients receiving Piclidenoson 3mg demonstrated statistically significant improvement compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response - Piclidenoson 3mg: 9.7% vs. placebo: 2.6%.

• Related: Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study.

• Secondary endpoint parameters at week 32 comparing Piclidenoson to the active control drug, Amgen Inc's (NASDAQ: AMGN) Otezla (apremilast), revealed inferiority related to PASI 75 (17% vs. 26.2%) and PASI 50 (34.1% vs. 49.5%).

• But revealed the superiority of Piclidenoson compared to Otezla in the Psoriasis Disability Index (PDI) (20.5% vs. 10.3%).

• Piclidenoson showed a favorable safety profile.

• Price Action: CANF shares are up 33.8% at $1.19 during the premarket session on the last check Wednesday.

See more from Benzinga

• White House Outlines New Monkeypox Vaccine Strategy: What You Need To Know

• Troubled Grubhub's Parent Company Seeks Investment Partner: WSJ

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.